Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase II Treatment Closed no age specified MDA-MBDT-7932

Objectives

I.  Determine the therapeutic efficacy in terms of response rate and survival 
of weekly intravenous methyl-GAG therapy in patients who have failed higher 
priority protocols.
II.  Determine the qualitative and quantitative toxicity of such a treatment 
program.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with measurable lesions of 
metastatic breast cancer who have failed on first or second priority 
protocols.  Patients must have a life expectancy of at least 12 weeks, a 
Zubrod Performance Score of 3 or more, and adequate bone marrow, liver and 
renal function.  All prior therapy must have concluded 4 weeks prior to entry, 
w ith recovery from all toxic effects.

Expected Enrollment

Protocol closed 09/80.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  Methyl-GAG, MeGAG, NSC-32946.

Trial Contact Information

Trial Lead Organizations

M. D. Anderson Cancer Center at University of Texas

Eugene M. McKelvey, MD, Protocol chair		Ph: 713-792-2570; 800-392-1611